Neurocrine Biosciences NBIX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's free cash flow yield?
- Neurocrine Biosciences (NBIX) reported free cash flow yield of 6.3% in Q1 2026.
- How has Neurocrine Biosciences's free cash flow yield changed year-over-year?
- Neurocrine Biosciences's free cash flow yield increased by 40.9% year-over-year, from 4.5% to 6.3%.
- What is the long-term trend for Neurocrine Biosciences's free cash flow yield?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's free cash flow yield has grown at a 9.6% compound annual growth rate (CAGR), from 12.6% to 18.2%.
- What does free cash flow yield mean?
- The spendable cash the business throws off each year as a percentage of its market price.
- How do you interpret free cash flow yield?
- Higher yield can mean better value — you pay less for each dollar of cash generated. A useful sanity check against earnings-based multiples, which non-cash items can distort.
- How does free cash flow yield compare across companies?
- Comparable across cash-generative companies; less meaningful for firms in heavy-investment phases with temporarily negative FCF.